Published in Hepatitis Weekly, March 28th, 2005
According to researchers in the Peoples Republic of China, "we have investigated the characteristics of lamivudine-resistant strains in patients with chronic hepatitis B in Guangdong, China, where the predominant genotypes are B and C. Two hundred forty-seven patients treated with lamivudine in Nanfang Hospital were followed-up."
"Patients with hepatitis B e antigen (HBeAg) positive and hepatitis B virus (HBV)-DNA levels over 7.5 x 106 copies/ml at baseline had a shorter time to the selection of YMDD mutant (p=0.02 and 0.00, respectively)," said J. Sun and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly